Pier Capital LLC lowered its holdings in Repligen Co. (NASDAQ:RGEN) by 15.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 147,939 shares of the biotechnology company’s stock after selling 27,626 shares during the period. Pier Capital LLC owned approximately 0.34% of Repligen worth $5,669,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. OxFORD Asset Management LLP lifted its holdings in shares of Repligen by 421.5% in the third quarter. OxFORD Asset Management LLP now owns 31,357 shares of the biotechnology company’s stock valued at $1,200,000 after purchasing an additional 25,344 shares in the last quarter. Brown Advisory Inc. purchased a new stake in shares of Repligen in the third quarter valued at $310,000. Schwab Charles Investment Management Inc. lifted its holdings in shares of Repligen by 4.1% in the third quarter. Schwab Charles Investment Management Inc. now owns 224,388 shares of the biotechnology company’s stock valued at $8,599,000 after purchasing an additional 8,938 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Repligen by 9.1% in the third quarter. Legal & General Group Plc now owns 74,927 shares of the biotechnology company’s stock valued at $2,870,000 after purchasing an additional 6,250 shares in the last quarter. Finally, American International Group Inc. lifted its holdings in shares of Repligen by 13.4% in the third quarter. American International Group Inc. now owns 29,476 shares of the biotechnology company’s stock valued at $1,130,000 after purchasing an additional 3,479 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.
Repligen Co. (NASDAQ RGEN) opened at $34.34 on Tuesday. Repligen Co. has a one year low of $28.48 and a one year high of $46.81. The firm has a market cap of $1,547.00, a price-to-earnings ratio of 61.22, a PEG ratio of 2.31 and a beta of 1.04.
Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.11 by $0.04. Repligen had a net margin of 16.93% and a return on equity of 7.57%. The business had revenue of $36.58 million for the quarter, compared to the consensus estimate of $35.69 million. During the same period in the prior year, the business posted $0.08 earnings per share. Repligen’s revenue for the quarter was up 48.2% compared to the same quarter last year. equities research analysts predict that Repligen Co. will post 0.61 EPS for the current fiscal year.
A number of research firms have recently issued reports on RGEN. Stephens restated an “overweight” rating and issued a $50.00 target price on shares of Repligen in a report on Tuesday, September 26th. Jefferies Group restated a “hold” rating and issued a $40.00 target price on shares of Repligen in a report on Thursday, September 14th. BidaskClub upgraded Repligen from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. TheStreet upgraded Repligen from a “c+” rating to a “b-” rating in a report on Friday, August 11th. Finally, Zacks Investment Research upgraded Repligen from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a report on Saturday, August 12th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $44.67.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/05/repligen-co-rgen-shares-sold-by-pier-capital-llc.html.
Repligen Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Co. and related companies with MarketBeat.com's FREE daily email newsletter.